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Cardiac magnetic resonance imagingAims: In Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), electrophysiological pathology has
been claimed to precede morphological and functional pathology. Accordingly, an ECG without ARVC
markers should be rare in ARVC patients with pathology identified by cardiac imaging. We quantified
the prevalence of ARVC patients with evidence of structural disease, yet without ECG Task Force Criteria
(TFC).
Methods and results: We included 182 probands and family members with ARVC-associated mutations
(40 ± 17 years, 50% women, 73% PKP2 mutations) from the Nordic ARVC Registry in a cross-sectional
analysis. For echocardiography and cardiac MR (CMR), we differentiated between “abnormalities” and
TFC. “Abnormalities” were defined as RV functional or structural measures outside TFC reference values,
without combinations required to fulfill TFC. ECG TFC were used as defined, as these are not composite pa-
rameters. We found that only 4% of patients with ARVC fulfilled echocardiographic TFC without any ECG
TFC. However, importantly, 38% of patients had imaging abnormalities without any ECG TFC. These results
were supported by CMR data from a subset of 51 patients: 16% fulfilled CMR TFC without fulfilling ECG
TFC, while 24% had CMR abnormalities without any ECG TFC. In a multivariate analysis, echocardiographic
TFC were associated with arrhythmic events.
Conclusion: More than one third of ARVC genotype positive patients had subtle imaging abnormalities without
fulfilling ECG TFC. Although most patients will have both imaging and ECG abnormalities, structural abnormali-
ties in ARVC genotype positive patients cannot be ruled out by the absence of ECG TFC.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372 Oslo, Norway / PO Box 4950 Nydalen, 0424 Oslo, Norway.
Haugaa).
bility and freedom from bias of the data presented and their discussed interpretation.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC2) is an
inherited disease resulting in electrophysiological abnormalities and po-
tentially fatal arrhythmias, as well as contractile dysfunction that most
commonly involves the right ventricle (RV), but can also affect the left
ventricle or both [1]. The diagnosis of ARVC is complex and summarized
in the 2010 modified Task Force Criteria (TFC) [2]. Genetic testing of
ARVC families has resulted in identification of ARVC-related mutations
even in patients without or with only mild disease phenotype, and en-
abled studies on early signs of disease [3]. Early detection of ARVC is cru-
cial, as ventricular arrhythmias may be the first disease manifestation
[4–6]. Previous studies have proposed a “concealed phase” of ARVC
with increased risk of ventricular arrhythmias before the occurrence of
structural changes [7,8]. However, recent studies have identified simulta-
neous occurrence of electrocardiographic and echocardiographic
changes in early disease [9]. We aimed to quantify the proportion of
ARVC patients that have structural changes identified by common imag-
ingmethods, butwithout electrophysiological changes identifiedby ECG.
2. Methods
2.1. Study population and data inclusion
Data for this cross-sectional study were extracted from the Nordic
ARVC Registry. At data extraction, the registry included 631 patients
with ARVC and their first-degree relatives enrolled from eight centers
in Norway, Denmark, and Sweden. The registry comprises clinical char-
acteristics, mutation status, and the results of diagnostic assessments by
ECG, echocardiography, and CMR as previously reported [10]. These
data are the results of evaluations performed by experts on ARVC at
each participating center. Data were extracted on December 14th
2016. The study was approved by the Regional Committees for Medical
Research Ethics, and all patients in the registry signed an informed con-
sent form, except for Denmark where approval by an ethics committee
is not needed for observational registries. The inclusion and use of data
complied with the Declaration of Helsinki.
All probands and relatives in the registrywith amutation considered
pathogenic for ARVC (major TFC criterion) were included. Based on this
inclusion criteria, by definition all patients fulfilled criteria for the diag-
nosis of possible, borderline or definite ARVC according to 2010 TFC [2].
The diagnosis of all patients in the registry is based on all TFC, which
comprises criteria based on cardiac morphological and functional mea-
surements from imaging, data from ECG and signal averaging ECG, his-
tory of arrhythmias, family history and presence of mutations
associated with ARVC. A definite diagnosis is fulfilled by two major, or
one major and two minor criteria, or four minor criteria from different
categories; a borderline diagnosis is fulfilled by one major and one
minor, or three minor criteria from different categories; and a possible
diagnosis is fulfilled by one major or two minor criteria from different
categories. We used the first available data in the registry for each pa-
tient, but for inclusion, ECG and echocardiographic data had to be avail-
able from the same calendar year. In a subset of patients, CMRdatawere
also available from the same calendar year.
2.2. Individual abnormalities vs. Task Force Criteria
All analyses were based on reference values as provided in the 2010
TFC [2]. To increase the sensitivity for structural changes, we also de-
fined the term “individual abnormality” for findings associated with
ARVC that are outside echocardiography and CMR TFC reference values,2 ARVC Arrhythmogenic Right Ventricular Cardiomyopathy; CMR Cardiac Magnetic
Resonance; FAC Fractional Area Change; PLAX Parasternal Long Axis; PSAX Parasternal
Short Axis; RV Right Ventricle; RVOT Right Ventricular Outflow Tract; TFC Task Force
Criteriabut not necessarily fulfill the combination of akinesia or dyskinesia to-
gether with right ventricular outflow tract (RVOT) and RV fractional
area change (RV FAC) cutoffs according to the 2010 TFC [2]. We also
combined CMR and echocardiographic data in an analysis of “individual
imaging abnormalities” and “imaging TFC”, respectively. A similar sepa-
ration of TFC and individual abnormalities was not performed for ECG,
as ECG TFC are not composite criteria, as opposed to imaging TFC. We
therefore used ECG TFC throughout the comparisons.
2.3. ECG data
We recorded the presence of T-wave inversion (TWI) in precordial
leads, Epsilon wave, and the terminal activation duration of the QRS
complex. Presence of RBBB was also noted, but was only considered
ARVC-associated when combined with TWI in V1-V4. We defined
“ECG TFC” as either minor or major ECG TFC [2].
2.4. Echocardiographic data
We collected 2D echocardiographic data according to reference
values from TFC [2]: PLAX RVOT ≥32 mm (major) or ≥ 29 mm
(minor); PSAX RVOT ≥36 mm (major) or ≥ 32 mm (minor); RV
FAC ≤ 33% (major) or ≤ 40% (minor). The presence of RV akinesia, dyski-
nesia or aneurysm was noted. We defined “echocardiographic TFC” as
measurements fulfilling minor or major TFC, i.e. RVOT or RV FAC mea-
sures outside TFC reference values combined with akinesia, dyskinesia
or aneurysm identified from qualitative assessments. “Individual echo-
cardiographic abnormalities” were defined as any measurements out-
side of the TFC reference values, e.g.: PLAX RVOT ≥29 was considered
an “abnormality”, but not a TFC unless RV akinesia, dyskinesia or aneu-
rysm were present.
2.5. Cardiac MR data
We registered CMR data according to reference values from TFC [2].
CMR TFC reference values for major criteria are: Ratio of RV end-
diastolic volume to body surface area (BSA) ≥ 110 mL/m2 for males
or ≥ 100mL/m2 for females, andRVFAC ≤ 40%. CMRTFC reference values
for minor criteria are: Ratio of RV end-diastolic volume to BSA ≥100mL/
m2 for males or ≥ 90 mL/m2 for females, and RV FAC ≤ 45%. We defined
“CMR TFC” as measurements fulfilling minor or major TFC, i.e. RV end-
diastolic volume or RV FACmeasures outside TFC reference values com-
binedwith akinesia, dyskinesia or dyssynchronous RV contraction iden-
tified by qualitative assessments. “Individual CMR abnormalities” were
defined as any measurements outside of the TFC reference values, but
not a TFC unless akinesia, dyskinesia or dyssynchronous RV contraction
were present.
2.6. Genetic analyses
Peripheral bloodwas used for isolation of genomic DNA, and genetic
analysis was performed as previously described [11]. The analyses were
performed at each participating center. Tests were made for mutations
in the following genes: plakophilin-2 (PKP2), plakoglobin (JUP), desmo-
plakin (DSP), desmoglein-2 (DSG2), desmocollin-2 (DSC2), transmem-
brane protein 43 (TMEM43), ryanodine receptor type 2 (RyR2). We
used the definition of pathogenic mutations provided in the 2010 TFC
[2]. Only individuals carryingmutations considered pathogenic or likely
pathogenic were included. The genetic analyses were performed at the
discretion of each participating center using the techniques available at
the time of evaluation.
2.7. Arrhythmic events
Patients with arrhythmic events were defined as those who origi-
nally were evaluated for ARVC due to ventricular arrhythmias and
Table 1
Clinical characteristics and prevalence of ARVC-associated abnormalities in 182 patients.
All
N = 182
Probands
N = 65
Family
members
N = 117
P
N % N % N %
Women 91 50 25 39 66 56 0.03
Probands 65 36
Age (years±SD) 40 ± 17 43 ± 15 39 ± 17
Definite ARVC diagnosis 95 52 60 92 35 30 b 0.0001
Borderline ARVC diagnosis 32 18 3 5 29 25 b 0.001
Possible ARVC diagnosis 55 30 2 3 53 45 b 0.0001
Mutations (All major TFC)
Plakophilin-2, PKP2 133 73 49 75 84 72 0.66
Desmoglein-2, DSG2 23 13 6 9 17 15 0.24
Desmoplakin, DSP 12 7 6 9 6 5 0.29
Transmembrane protein 43, TMEM43 8 4 2 3 6 5 0.52
Desmocollin-2, DSC2 4 2 1 2 3 3 0.68
Plakoglobin, JUP 1 1 0 0 1 1 0.42
Ryanodine receptor type 2, RYR2 1 1 1 2 0 0 0.13
ECG
TWI in V1 and V2 (Minor TFC) 67 37 44 68 23 20 b 0.0001
TWI in V1-V3 or more in absence of complete RBBB (Major TFC) 53 29 36 55 17 15 b 0.0001
TWI in V1-V4 and RBBB (Minor TFC) 2 1 1 2 1 1 0.57
TWI in V4, V5 or V6 (Minor TFC) 35 19 27 42 8 7 b 0.0001
Epsilon wave (Major TFC) 6 3 5 8 1 1 0.01
Terminal activation duration of QRS N55 ms (Minor TFC) 10 6 8 12 2 2 0.005
Any of the ECG abnormalities above 74 41 50 77 24 21 b 0.0001
Any TFC for ECG 74 41 50 77 24 21 b 0.0001
Echocardiography
Regional RV akinesia or dyskinesia 58 32 41 63 17 15 b 0.0001
RV aneurysm 36 20 26 40 10 9 b 0.0001
PLAX RVOT ≥32 mm (Major TFC if regional RV akinesia, dyskinesia, or aneurysm) 87 48 42 65 45 39 b 0.001
≥29 to b32 mm (Minor TFC if regional RV akinesia or dyskinesia) 27 15 6 9 21 18 0.10
PSAX RVOT ≥36 mm (Major TFC if regional RV akinesia, dyskinesia, or aneurysm) 46 25 26 40 20 17 b 0.001
≥32 to b36 mm (Minor TFC if regional RV akinesia or dyskinesia) 33 18 8 12 25 21 0.13
RV FAC ≤33% (Major TFC if regional RV akinesia, dyskinesia, or aneurysm) 24 13 8 12 8 7 0.26
N33% to ≤40% (Minor TFC if regional RV akinesia or dyskinesia) 31 17 13 20 19 16 0.50
Any of the echocardiographic abnormalities above 134 74 54 83 80 68 0.03
Any Task Force Criteria for echocardiography 53 29 39 60 14 12 b 0.0001
Arrhythmias
Contact due to arrhythmic events 55 30 47 72 8 7 b 0.0001
Arrhythmias major TFC (VT with LBBB morphology and superior axis) 32 18 28 43 4 3 b 0.0001
Arrhythmias minor TFC (VT of RVOT config. or unknown axis or N 500 VES/24 h) 42 23 29 45 13 11 b 0.0001
Data are presented as number of cases and percentage of population unless otherwise stated. BSA Body surface area, CMR Cardiac magnetic resonance, FAC Fractional area change, LBBB
Left bundle branch block, PLAX Parasternal long axis, PSAX Parasternal short taxis, RBBB Right bundle branch block, RV Right ventricle, RVOTRight ventricular outflow tract, TFC Task force
criteria, TWI T wave inversion, VT Ventricular tachycardia. P value for probands vs relatives. Bold indicates the main take-home-data that are directly refered to in the text.
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sustained ventricular tachycardia of left bundle-branch morphology
with superior axis), and minor arrhythmia TFC (non-sustained or
sustained ventricular tachycardia of RV outflow tract configuration,
left bundle-branch block morphology with inferior axis or of unknown
axis, or ≥ 500 ventricular extra systoles per 24 h).
2.8. Statistical analysis
Nominal and categorical data were presented as number of cases
and percentage of a population, and were analyzed by Chi-square,
Fischer's exact test, or N-1 Chi-square. Continuous variables were pre-
sented as mean ± standard deviation and were analyzed by t-tests.
Bonferroni corrections were used for multiple comparisons. Logistic re-
gression analyses were performed with arrhythmic events as depen-
dent variable. P-values b.05 were considered statistically significant.
3. Results
3.1. Study population
We included 182 probands and family members from 88 families
with a mutation considered pathogenic for ARVC (Table 1). The mean
age at first available examination was 40 ± 17 years, 50% werewomen, and 65 patients (36%) were probands (Table 1). Fifty-five pa-
tients (30%) fulfilled criteria for possible, 32 (18%) borderline, and 95
(52%) fulfilled criteria for definite ARVC diagnosis. The most commonly
affected gene was PKP2 (133 patients, 73%), followed by DSG2 (23 pa-
tients, 13%), while mutations in other genes were comparably rare
(Table 1). CMR data were available from 51 patients (28%) in whom
the background data were similar to the total population (Supplemen-
tary Tables 1 and 2).
3.2. Prevalence of patients with structural changes without ECG changes
We identified the proportion of patients that had structural changes
as identified by cardiac echocardiography, but not electrophysiological
changes identified by ECG (Fig. 1).We found that only 4% of patients ful-
filled echocardiographic TFC, and still had no TFC in the ECG (Fig. 1,
upper panel). To increase the sensitivity for structural abnormalities,
we also performed a similar analysis with “individual echocardio-
graphic abnormalities” using the parameter values for RVOT diameter
and RVFAC used in the TFC, but without demanding the combination
with RV akinesia, dyskinesia or aneurysm required to fulfill TFC. By
this analysis, 38% of patients had echocardiographic abnormalities, yet
without TFC in the ECG (Fig. 1, upper panel).
We validated the echocardiographic findings by repeating the anal-
yses with data from CMR. We found that 16% of patients fulfilled CMR
Fig. 1. Upper left panel: Percentage of patients with ECG TFC without echocardiographic TFC (ECG +/echo. -), and with echocardiographic TFC without ECG TFC (Echo +, ECG -),
respectively. Upper right panel: Corresponding data with the use of echocardiographic abnormalities as opposed to TFC. Middle panels: Corresponding data from CMR, with use of CMR
TFC in the left panel, and CMR abnormalities in the right panel. Lower panels: Corresponding data from echocardiographic and CMR combined as “imaging”.
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the sensitivity by using individual abnormalities, 24% of patients had ab-
normalities identified by CMR without fulfilling TFC in the ECG (Fig. 1,
middle panel).
In a third analysis, we combined data from echocardiography and
CMR. We found that 7% of patients had structural changes as defined
by the TFC for echocardiography and/or CMR without TFC in the ECG
(Fig. 1, lower panel). In the more sensitive analysis using individual ab-
normalities, 39% of patients had structural abnormalities identified by
echocardiography and/or CMR without electrophysiological changes
as defined by TFC for ECG (Fig. 1, lower panel).3.3. Subgroup analysis
We performed a separate analysis of family members (Table 1). We
found that 4% of familymembers fulfilled echocardiographic TFCwithoutTFC in the ECG.When individual abnormalitieswere considered, 51%had
echocardiographic abnormalities without fulfilling TFC in the ECG.
Results for diagnostic subgroups (possible, borderline, definite) are
shown in Supplementary Table 3.3.4. Patients with no TFC-defined ECG changes
We further analyzed the subgroup of patients that did not fulfill any
ECG TFC (N = 108, 59% of all patients, Table 2). Among these patients,
7% fulfilled echocardiographic TFC, while by the more sensitive ap-
proach, echocardiographic abnormalities were found in 64%. The ac-
cording number for CMR were 34% that fulfilled CMR TFC, while 52%
had CMR abnormalities (Table 2).When data from the two imagingmo-
dalities were combined, 11% fulfilled echocardiographic and/or CMR
TFC, while more subtle imaging abnormalities were identified in 66%
(Table 2).
Table 2
Imaging in 108 patients with no TFC-defined ECG changes.
N %
Age 37 ± 17
Women 62 57
Echocardiography in patients with no ECG TFC (N = 108 of 182 patients in total)
Any echocardiographic TFC 8 7
Any echocardiographic abnormalities 69 64
CMR in patients with no ECG TFC (N = 23 of 51 patients with available CMR)
Any CMR TFC 8 34
Any CMR abnormalities 12 52
Imaging (echocardiography and CMR combined) in patients with no ECG TFC
(N = 108 of 182 patients in total)
Any imaging TFC 12 11
Any imaging abnormalities 71 66
Echocardiography in probands with no ECG TFC (N = 15 of 65 probands in
total)
Probands - Any echocardiographic TFC 3 20
Probands - Any echocardiographic abnormalities 9 60
Echocardiography in family members with no ECG TFC (N = 93 of 117 family
members in total)
Family members - Any echocardiographic TFC 5 5
Family members - Any echocardiographic abnormalities 60 65
Data presented as number of cases and percentage of the specified population, except for
age (±SD).
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(N = 93, 79% of all family members): 5% fulfilled echocardiographic
TFC, while 65% had individual echocardiographic abnormalities
(Table 2).3.5. Association between abnormalities, TFC and arrhythmias
In our population, arrhythmic events led to the original contact in
30% of patients (the remaining patients were evaluated as part of familyFig. 2. Prevalence of ventricular arrhythmias according to combinations of ECG TFC and echoc
events across four groups of patients with different combinations of ECG TFC and echocardio
groups of patients defined by coexistence of ECG TFC and echocardiographic (echo.) abnorma
defined by coexistence of ECG TFC and echocardiographic (echo.) TFC.screening or other symptoms), and 41% of patients fulfilled eithermajor
or minor TFC for arrhythmias (Table 1). Arrhythmic events were associ-
ated with both ECG TFC (OR 9.2, 95% CI 4.7–18.3, P b .0001), individual
echocardiographic abnormalities (OR 2.3, 95% CI 1.1–4.6, P b .05), and
echocardiographic TFC (OR 9.9, 95% CI 4.7–21.2, P b .0001) (Fig. 2).
However, in a multivariate logistic regression analysis, only ECG TFC
(OR 4.8, 95% CI 2.2–10.5, P b .001) and echocardiographic TFC (OR 4.4,
95% CI 1.9–10.4, P b .001) were independently associated with arrhyth-
mic events.
4. Discussion
We found that only 4% of patients with ARVC have structural disease
as defined by echocardiographic TFC without any TFC in the ECG. How-
ever, we also showed that 38% of patients had individual echocardio-
graphic abnormalities without fulfilling ECG TFC. Importantly, only
TFC were independently associated with arrhythmic events in a multi-
variate analysis.
4.1. A large subset of patients without ARVC-associated ECG TFC have indi-
vidual echocardiographic abnormalities
Previous studies have indicated that electrophysiological abnormal-
ities occur first in ARVC [7]. Ourfindings supported this ideawhen using
imaging and ECG TFC. However, when using individual imaging abnor-
malities outside reference values, a large subset of patients had imaging
abnormalities without concurrent ECG TFC. These findings suggest that
a considerable number of patients have structurally manifest and de-
tectable disease before they have changes in the ECG that fulfill TFC.
Most likely, electrical and structural manifestations occur simulta-
neously, and the seemingly temporal separation is only due to the lim-
itations of current diagnostic tools. Recent studies have reported that
early signs of structural disease occur before other ARVCmanifestationsardiographic abnormalities or TFC. Modified radar plots of the distributions of arrhythmic
graphic abnormalities or TFC. A) Percentages of patients with arrhythmic events in four
lities (abn.). B) Percentages of patients with arrhythmic events in four groups of patients
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niques that can detect subtle changes [9].
The percentage of patients with evidence of structural disease with-
out ECG TFC was lower when imaging TFC were used than when indi-
vidual abnormalities were considered (7% versus 38%). This can be
explained by the fact that imaging TFC have a higher specificity than in-
dividual abnormalities, at a cost of lower sensitivity. Fulfilled imaging
TFC reflects more advanced ARVC disease, and is therefore more likely
to be accompanied by ECG pathology [9,12]. Indeed, the separation be-
tween formal imaging TFC and individual abnormalities in our analysis
increased the sensitivity, and thereby included more subtle structural
pathology even by still using standard andwell-established echocardio-
graphic parameters. Furthermore, in patientswith noECGTFC,more pa-
tients fulfilled CMR TFC than echocardiography TFC. These results
support that CMR TFC are more sensitive to detect ARVC compared to
echocardiographic TFC, as reported previously [10,13,14].4.2. Clinical implications
Although the aim of our study was to identify the proportion of pa-
tients with evidence of structural disease despite no ECG TFC, it is im-
portant to emphasize the notable sensitivity and specificity of ECG
TFC, as also shown by our data. Indeed, our data support the use of sev-
eral diagnostic modalities since pathology identified by echocardiogra-
phy, CMR and ECG can be present independently or combined. Also,
with increasing awareness of ARVC and improved availability and better
resolution of cardiac imaging techniques, there may now even be a risk
of over-diagnosing ARVC [15]. E.g., in competitive athletes, a substantial
proportion fulfills ARVC imaging criteria with dilation of RVOT without
fulfilling TFC for ARVC [16–18]. As our study shows, improved diagnos-
tic tools to identify true ARVC are highly needed.4.3. Limitations and future studies
The fact that echocardiographic TFC are combinations of parameters,
while ECG criteria are not, affects our comparison of “individual abnor-
malities” to TFC. We do not claim that minor echocardiographic abnor-
malities are equivalent to ARVC penetrance, but we want to highlight
that structural changes can appear in absence of ECG TFC. Using individ-
ual imaging abnormalities will increase sensitivity, while the combina-
tion of several abnormalities needed to fulfill imaging TFC will
increase specificity of ARVC diagnosis. Several ECG and imaging param-
eters have been presented after the publication of the 2010 TFC, which
might be considered in a future TFC re-evaluation. We did not include
signal average ECG (SAECG) due to incomplete data.
We included genotype positive ARVC patients irrespective of TFC
status to separate inclusion data from outcome data. Families with neg-
ative, uncertain, or unknown genetic data were therefore excluded. We
cannot exclude that in thework-up of patients, information about geno-
type might have affected the interpretation of imaging findings, and
minor echocardiographic abnormalities may have been over-
interpreted. Also, a largemajority (73%) of patients in our study popula-
tion had PKP2 mutations, in line with other study populations, which
may have influenced our data.
The Nordic ARVC registry is a multi-center registry, based on regis-
tration of data by experts in each center. The lack of a core-lab for echo-
cardiographic, CMR and genetic assessment is a limitation of this
registry. We limited our evaluation to standard echocardiographic pa-
rameters and standard ECG as defined by the TFC to make our data rel-
evant for the early diagnostic evaluation of patients in everyday clinical
practice. Data on left ventricular characteristics and more advanced
echocardiographic parameters, such as measurements of myocardial
strain are therefore not included in the registry, but may enable even
earlier detection of cardiac dysfunction in ARVC [9,19].5. Conclusion
ARVC structural and ECG abnormalities may coexist or occur inde-
pendently, but the prevalence strongly depend on the criteria that are
used. More than one third of ARVC genotype positive patients had sub-
tle imaging signs of disease without fulfilling ECG TFC. Although most
patients will have both imaging and ECG abnormalities, disease pene-
trance in ARVC genotype positive patients cannot be ruled out by the
absence of ECG TFC.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2020.05.095.
Acknowledgements
The Nordic ARVC registry received an unrestricted research grant
from Medtronic, Denmark, covering costs for establishing and mainte-
nance of the database for the period 2009–2015.
Dr. Platonov has received funding from The Swedish Heart-Lung
Foundation (grant #20180444), andDonation funds at SkaneUniversity
Hospital (Lund, Sweden) and governmental funding of clinical research
by the Swedish healthcare system (ALF40702).
Declaration of Competing Interests
None declared.
References
[1] D. Corrado, C. Basso, D.P. Judge, Arrhythmogenic cardiomyopathy, Circ. Res. 121
(2017) 784–802.
[2] F.I. Marcus, W.J. McKenna, D. Sherrill, C. Basso, B. Bauce, D.A. Bluemke, et al., Diagno-
sis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modi-
fication of the task force criteria, Circulation. 121 (2010) 1533–1541.
[3] S. Sen-Chowdhry, P. Syrris, W.J. McKenna, Role of genetic analysis in the manage-
ment of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy,
J. Am. Coll. Cardiol. 50 (2007) 1813–1821.
[4] J.A. Groeneweg, A. Bhonsale, C.A. James, A.S. te Riele, D. Dooijes, C. Tichnell, et al.,
Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic
right ventricular dysplasia/cardiomyopathy patients and family members, Circ.
Cardiovasc. Genet. 8 (2015) 437–446.
[5] J.S. Hulot, X. Jouven, J.P. Empana, R. Frank, G. Fontaine, Natural history and risk strat-
ification of arrhythmogenic right ventricular dysplasia/cardiomyopathy, Circulation.
110 (2004) 1879–1884.
[6] H. Calkins, D. Corrado, F. Marcus, Risk stratification in arrhythmogenic right ventric-
ular cardiomyopathy, Circulation. 136 (2017) 2068–2082.
[7] G. Thiene, A. Nava, D. Corrado, L. Rossi, N. Pennelli, Right ventricular cardiomyopa-
thy and sudden death in young people, N. Engl. J. Med. 318 (1988) 129–133.
[8] A.S. te Riele, C.A. James, N. Rastegar, A. Bhonsale, B. Murray, C. Tichnell, et al., Yield of
serial evaluation in at-risk family members of patients with ARVD/C, J. Am. Coll.
Cardiol. 64 (2014) 293–301.
[9] I.S. Leren, J. Saberniak, T.F. Haland, T. Edvardsen, K.H. Haugaa, Combination of ECG
and echocardiography for identification of arrhythmic events in early ARVC, JACC
Cardiovasc. Imaging 10 (2017) 503–513.
[10] R. Borgquist, K.H. Haugaa, T. Gilljam, H. Bundgaard, J. Hansen, O. Eschen, et al., The
diagnostic performance of imaging methods in ARVC using the 2010 task force
criteria, Eur. Heart J. Cardiovasc. Imaging 15 (2014) 1219–1225.
[11] J. Saberniak, N.E. Hasselberg, R. Borgquist, P.G. Platonov, S.I. Sarvari, H.J. Smith, et al.,
Vigorous physical activity impairs myocardial function in patients with arrhythmo-
genic right ventricular cardiomyopathy and in mutation positive family members,
Eur. J. Heart Fail. 16 (2014) 1337–1344.
[12] S.I. Sarvari, K.H. Haugaa, O.G. Anfinsen, T.P. Leren, O.A. Smiseth, E. Kongsgaard, et al.,
Right ventricular mechanical dispersion is related tomalignant arrhythmias: a study
of patients with arrhythmogenic right ventricular cardiomyopathy and subclinical
right ventricular dysfunction, Eur. Heart J. 32 (2011) 1089–1096.
[13] K.H. Haugaa, C. Basso, L.P. Badano, C. Bucciarelli-Ducci, N. Cardim, O. Gaemperli,
et al., Comprehensive multi-modality imaging approach in arrhythmogenic
cardiomyopathy-an expert consensus document of the European Association of Car-
diovascular Imaging, Eur. Heart J. Cardiovasc. Imaging 18 (2017) 237–253.
[14] A. Müssigbrodt, H. Knopp, C. Czimbalmos, C. Jahnke, S. Richter, D. Husser, et al.,
Exercise-related sudden cardiac death of an American football player with arrhyth-
mogenic right ventricular dysplasia/cardiomyopathy AND sarcoidosis, Clin Case
Rep. 7 (2019) 686–688.
[15] A. Zaidi, N. Sheikh, J.K. Jongman, S. Gati, V.F. Panoulas, G. Carr-White, et al., Clinical
differentiation between physiological remodeling and arrhythmogenic right ven-
tricular cardiomyopathy in athletes with marked electrocardiographic repolariza-
tion anomalies, J. Am. Coll. Cardiol. 65 (2015) 2702–2711.
[16] F. D’Ascenzi, C. Pisicchio, S. Caselli, F.M. Di Paolo, A. Spataro, A. Pelliccia, RV remod-
eling in Olympic athletes, JACC Cardiovasc. Imaging 10 (2017) 385–393.
158 M.K. Stokke et al. / International Journal of Cardiology 317 (2020) 152–158[17] A. Zaidi, S. Ghani, R. Sharma, D. Oxborough, V.F. Panoulas, N. Sheikh, et al., Physiolog-
ical right ventricular adaptation in elite athletes of African and Afro-Caribbean ori-
gin, Circulation. 127 (2013) 1783–1792.
[18] C. Czimbalmos, I. Csecs, Z. Dohy, A. Toth, F.I. Suhai, A. Mussigbrodt, et al., Cardiac
magnetic resonance based deformation imaging: role of feature tracking in athletes
with suspected arrhythmogenic right ventricular cardiomyopathy, Int. J. Card. Imag-
ing 35 (2019) 529–538.[19] T.P. Mast, K. Taha, M.J. Cramer, J. Lumens, J.F. van der Heijden, B.J. Bouma, et al., The
Prognostic value of right ventricular deformation imaging in early arrhythmogenic
right ventricular cardiomyopathy, JACC Cardiovasc. Imaging 12 (3) (2019)
446–455, https://doi.org/10.1016/j.jcmg.2018.01.012.
